Pradžia › Berkito limfoma › Washington
Berkito limfoma klinikiniai tyrimai Washington
11 tyrimai dėl Berkito limfoma ieško dalyvių vietose Washington.
Miestai Washington
Oficialus tyrimo tekstas (anglų kalba)
A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
Renkami dalyviai2 fazė
366 Days – 46 Years · Visoms lytims · Atnaujinta 2026-10-02 · NCT06124157Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
Renkami dalyviai2 fazė
365 Days · Visoms lytims · Atnaujinta 2026-09-25 · NCT06317662Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
- Fred Hutchinson Cancer Research Center, Seattle
Renkami dalyviai3 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-09-21 · NCT07648264A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
- ir dar 1
Renkami dalyviai2 fazė
Amžius nuo 1 iki 30 · Visoms lytims · Atnaujinta 2026-09-01 · NCT04546399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Seattle Children's Hospital, Seattle
- Providence Sacred Heart Medical Center and Children's Hospital, Spokane
- Mary Bridge Children's Hospital and Health Center, Tacoma
Renkami dalyviai3 fazė
365 Days – 25 Years · Visoms lytims · Atnaujinta 2026-08-25 · NCT03959085Evaluating the Effects of Hemoglobin Threshold-specific Packed Red Blood Cell Transfusions on Quality of Life and Functional Outcomes in Patients With High-grade Myeloid Neoplasms, Acute Myeloid Leukemia, or B Acute Lymphoblastic Lymphoma/Leukemia
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Renkami dalyviai
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-08-19 · NCT06710418Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Renkami dalyviai2 fazėLaukiami sveiki savanoriai
6 Months · Visoms lytims · Atnaujinta 2026-05-29 · NCT04195633Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin Lymphoma
- Fred Hutch/University of Washington Cancer Consortium, Seattle
Renkami dalyviai2 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-04-23 · NCT07097363Study of SGR-1505 in Mature B-Cell Neoplasms
- Fred Hutchinson Cancer Center, Seattle
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2026-02-13 · NCT05544019Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- Fred Hutchinson Cancer Research Center, Seattle
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2025-11-05 · NCT04260022Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
- Fred Hutchinson Cancer Center, Seattle
Renkami dalyviai1 fazė
Amžius 18 ir vyresni · Visoms lytims · Atnaujinta 2024-11-15 · NCT06034275Iš ClinicalTrials.gov, duomenys gauti 2026-10-05. Kiekvienas tyrimas nustato savo tinkamumo kriterijus; tyrimo komanda sprendžia, kas gali dalyvauti.